In CAD, Low HDL Cholesterol, High CRP Increases Mortality

Share this content:
After undergoing PCI, low HDL cholesterol and high CRP are linked to increased mortality in CAD.
After undergoing PCI, low HDL cholesterol and high CRP are linked to increased mortality in CAD.

(HealthDay News) — For patients with coronary artery disease (CAD) on statin therapy after undergoing a first percutaneous coronary intervention (PCI), the risk for all-cause mortality is increased with low HDL cholesterol evels and elevated C-reactive protein (CRP), according to a study published in The American Journal of Cardiology.

Manabu Ogita, MD, PhD, from Juntendo University Shizuoka Hospital in Japan, and colleagues examined the impact of inflammation on the correlation between HDL cholesterol and long-term outcomes in patients with CAD on statin therapy. 

A total of 3,507 consecutive patients with CAD who underwent a first PCI from 1997 to 2011 were enrolled. The 1,682 patients who had been treated with statins at the time of PCI were stratified into four groups according to HDL cholesterol and CRP levels. 

Patients were followed for a median of 1,985 days.

The researchers found that 11.7% of patients died because of cardiac death, carcinoma, stroke and other causes during follow-up. Among the groups, the rates of all-cause death varied significantly. 

Even after adjustment for other covariates, low HDL cholesterol with high CRP levels remained significantly associated with a higher rate of all-cause death (HR=2.38; P<.0001).

"Low HDL cholesterol together with elevated CRP levels is significantly associated with long-term outcomes in patients who received statin therapy after PCI," the researchers wrote.

Reference

  1. Ogita M et al. Am J Cardiol. 2015;116(7):999-1002.
You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus